UK regulatory authority (MHRA) has granted marketing authorization for Bimzelx (bimekizumab), a dual inhibitor of IL-17A
Tweet Content
UK regulatory authority (MHRA) has granted marketing authorization for Bimzelx (bimekizumab), a dual inhibitor of IL-17A & IL-17F; approved in adults w/ active psoriatic arthritis or axial spondyloarthritis (+/- MTX). Prev approved in EU June 2023 https://t.co/Hp5W1t6Acz https://t.co/6tZ1DN8TVo
Show on Archive Page
On
Display in Search Results
On
PDQ
Off